

8 Literaturverzeichnis

1. U.S. Renal Data System, U., *Annual Data Report, 2004: Atlas of End-Stage Renal Disease in the United States*, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2004.
2. Mall, G., *Interstitielle Myokardfibrose bei chronischer Urämie- Ursache der diastolischen Funktionsstörung bei Dialyse-Patienten?* Der Pathologe, 1989. **10**: p. 200-205.
3. Kleinknecht, C., D. Laouari, and M. Burtin, *Uremic rat model: experience with young rats*. Contrib Nephrol, 1988. **60**: p. 27-38.
4. Strauch, M. and N. Gretz, *Animal models to induce renal failure: a historical survey*. Contrib Nephrol, 1988. **60**: p. 1-8.
5. Shneyvays, V., et al., *Induction of apoptosis in cardiac myocytes by an A3 adenosine receptor agonist*. Exp Cell Res, 1998. **243**(2): p. 383-97.
6. Lucas, D.G., Jr., et al., *Cardiorenal effects of adenosine subtype 1 (A1) receptor inhibition in an experimental model of heart failure*. J Am Coll Surg, 2002. **194**(5): p. 603-9.
7. Neumann, J., et al., *Functional studies in atrium overexpressing A1-adenosine receptors*. Br J Pharmacol, 1999. **128**(7): p. 1623-9.
8. Peart, J. and J.P. Headrick, *Adenosine-mediated early preconditioning in mouse: protective signaling and concentration dependent effects*. Cardiovasc Res, 2003. **58**(3): p. 589-601.
9. Dubey, R.K., D.G. Gillespie, and E.K. Jackson, *Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: role of A2B receptors*. Hypertension, 1998. **31**(4): p. 943-8.
10. Kooman, J.P. and K.M. Leunissen, *Cardiovascular aspects in renal disease*. Curr Opin Nephrol Hypertens, 1993. **2**(5): p. 791-7.
11. Levin, A., et al., *Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention*. Am J Kidney Dis, 1996. **27**(3): p. 347-54.
12. London, G.M. and P.S. Parfrey, *Cardiac disease in chronic uremia: pathogenesis*. Adv Ren Replace Ther, 1997. **4**(3): p. 194-211.
13. London, G.M., *Left ventricular alterations and end-stage renal disease*. Nephrol Dial Transplant, 2002. **17 Suppl 1**: p. 29-36.
14. Levin, A. and R.N. Foley, *Cardiovascular disease in chronic renal insufficiency*. Am J Kidney Dis, 2000. **36**(6 Suppl 3): p. S24-30.
15. Heng, M.K., R.F. Janz, and J. Jobin, *Estimation of regional stress in the left ventricular septum and free wall: an echocardiographic study suggesting a mechanism for asymmetric septal hypertrophy*. Am Heart J, 1985. **110**(1 Pt 1): p. 84-90.
16. Parfrey, P.S., et al., *Outcome of congestive heart failure, dilated cardiomyopathy, hypertrophic hyperkinetic disease, and ischemic heart disease in dialysis patients*. Am J Nephrol, 1990. **10**(3): p. 213-21.
17. Wanner, C., K. Frommherz, and W.H. Horl, *Hyperlipoproteinemia in chronic renal failure: pathophysiological and therapeutic aspects*. Cardiology, 1991. **78**(3): p. 202-17.
18. Rostand, S.G., K.A. Kirk, and E.A. Rutsky, *Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease*. Kidney Int, 1982. **22**(3): p. 304-8.
19. Weber, K.T., et al., *Connective tissue and repair in the heart. Potential regulatory mechanisms*. Ann N Y Acad Sci, 1995. **752**: p. 286-99.
20. Brilla, C.G., B. Maisch, and K.T. Weber, *Myocardial collagen matrix remodelling in arterial hypertension*. Eur Heart J, 1992. **13 Suppl D**: p. 24-32.

21. Kramer, W., *Urämische Herzkrankheit. Ventrikeldynamik bei terminaler Niereninsuffizienz im Vergleich zur idiopathisch-dilatativen Kardiomyopathie*. Med Welt, 1985. **36**: p. 1317-1323.
22. Weber, K.T., et al., *Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium*. Circ Res, 1988. **62**(4): p. 757-65.
23. Morrison, G., et al., *Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients*. Kidney Int, 1980. **17**(6): p. 811-9.
24. Bakth, S., et al., *Arrhythmia susceptibility and myocardial composition in diabetes. Influence of physical conditioning*. J Clin Invest, 1986. **77**(2): p. 382-95.
25. Tyralla, K. and K. Amann, *Cardiovascular changes in renal failure*. Blood Purif, 2002. **20**(5): p. 462-5.
26. Block, G.A. and F.K. Port, *Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management*. Am J Kidney Dis, 2000. **35**(6): p. 1226-37.
27. Ganesh, S.K., et al., *Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients*. J Am Soc Nephrol, 2001. **12**(10): p. 2131-8.
28. Amann, K., et al., *Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia*. Kidney Int, 2003. **63**(4): p. 1296-301.
29. Mall, G., et al., *Myocardial interstitial fibrosis in experimental uremia--implications for cardiac compliance*. Kidney Int, 1988. **33**(4): p. 804-11.
30. Ritz, E., et al., *Is atherogenesis accelerated in uremia?* Contrib Nephrol, 1986. **52**: p. 1-9.
31. Rostand, S.G., K.A. Kirk, and E.A. Rutsky, *Dialysis-associated ischemic heart disease: insights from coronary angiography*. Kidney Int, 1984. **25**(4): p. 653-9.
32. Rostand, S.G., K.A. Kirk, and E.A. Rutsky, *The epidemiology of coronary artery disease in patients on maintenance hemodialysis: implications for management*. Contrib Nephrol, 1986. **52**: p. 34-41.
33. Parfrey, P.S., et al., *Congestive heart failure in dialysis patients*. Arch Intern Med, 1988. **148**(7): p. 1519-25.
34. van Es, A., et al., *Amelioration of cardiac function by L-carnitine administration in patients on haemodialysis*. Contrib Nephrol, 1992. **98**: p. 28-35.
35. Kramer, W., et al., *Cardiac dysfunction in patients on maintenance hemodialysis. II. Systolic and diastolic properties of the left ventricle assessed by invasive methods*. Contrib Nephrol, 1986. **52**: p. 110-24.
36. Klinke, R., Silbernagel, S., *Lehrbuch der Physiologie: Seite 128-132*. 1996, Stuttgart: Georg Thieme Verlag, 128-132.
37. Henrich, W.L., *Effects of dialysis on myocardial contractility*. Contrib Nephrol, 1986. **52**: p. 54-9.
38. Leunissen, K.M., et al., *Acetate versus bicarbonate hemodialysis in critically ill patients*. Nephron, 1986. **42**(2): p. 146-51.
39. Baldamus, C.A., et al., *Sympathetic and hemodynamic response to volume removal during different forms of renal replacement therapy*. Nephron, 1982. **31**(4): p. 324-32.
40. Low-Friedrich, I., et al., *Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients*. Am J Nephrol, 1991. **11**(1): p. 54-60.
41. Ritz, E., et al., *Cardiac changes in uremia and their possible relation to cardiovascular instability on dialysis*. Contrib Nephrol, 1990. **78**: p. 221-9.
42. Kooman, J.P., et al., *Role of the venous system in hemodynamics during ultrafiltration and bicarbonate dialysis*. Kidney Int, 1992. **42**(3): p. 718-26.
43. Pschyrembel, *Klinisches Wörterbuch*. 2005, Berlin: de Gruyter. 67.

44. Murphy, S.W., et al., *Comparative hospitalization of hemodialysis and peritoneal dialysis patients in Canada*. *Kidney Int*, 2000. **57**(6): p. 2557-63.
45. Locatelli, F., et al., *Hypertension and cardiovascular risk assessment in dialysis patients*. *Nephrol Dial Transplant*, 2004. **19**(5): p. 1058-68.
46. Rambausek, M., et al., *Blood pressure and uremic cardiomyopathy*. *Contrib Nephrol*, 1988. **60**: p. 230-5.
47. Zhang, Y.B., et al., *Altered cytosolic calcium homeostasis in rat cardiac myocytes in CRF*. *Kidney Int*, 1994. **45**(4): p. 1113-9.
48. Smogorzewski, M. and S.G. Massry, *Uremic cardiomyopathy: role of parathyroid hormone*. *Kidney Int Suppl*, 1997. **62**: p. S12-4.
49. Druke, T., et al., *Effect of parathyroidectomy on left-ventricular function in haemodialysis patients*. *Lancet*, 1980. **1**(8160): p. 112-4.
50. London, G.M., et al., *Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients*. *Kidney Int*, 1987. **32**(6): p. 900-7.
51. Amann, K., et al., *A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia*. *J Am Soc Nephrol*, 1994. **4**(10): p. 1814-9.
52. Lee, Y.S., *Alterations of ultrastructure and anionic molecular organization in the basement membranes of chronic uremic myocardium*. *Am J Nephrol*, 1986. **6**(6): p. 435-42.
53. Druml, W., et al., *Effects of acute and chronic uremia on active cation transport in rat myocardium*. *Kidney Int*, 1990. **38**(6): p. 1061-7.
54. Sun, D., et al., *Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors*. *Proc Natl Acad Sci U S A*, 2001. **98**(17): p. 9983-8.
55. Hori, M. and M. Kitakaze, *Adenosine, the heart, and coronary circulation*. *Hypertension*, 1991. **18**(5): p. 565-74.
56. Shryock, J.C. and L. Belardinelli, *Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology*. *Am J Cardiol*, 1997. **79**(12A): p. 2-10.
57. Mubagwa, K. and W. Flameng, *Adenosine, adenosine receptors and myocardial protection: an updated overview*. *Cardiovasc Res*, 2001. **52**(1): p. 25-39.
58. McKenzie, F.R. and G. Milligan, *Prostaglandin E1-mediated, cyclic AMP-independent, down-regulation of Gs alpha in neuroblastoma x glioma hybrid cells*. *J Biol Chem*, 1990. **265**(28): p. 17084-93.
59. Lehninger, A.L., Nelson D.L., Cox, M.M., *Prinzipien der Biochemie*. 1994, Verlag Spektrum Akademischer Verlag GmbH Heidelberg: Lehninger, A.L. 869-883.
60. Mullaney, I., et al., *Agonist activation of transfected human M1 muscarinic acetylcholine receptors in CHO cells results in down-regulation of both the receptor and the alpha subunit of the G-protein Gq*. *Biochem J*, 1993. **289** (Pt 1): p. 125-31.
61. Auchampach, J.A. and R. Bolli, *Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges*. *Am J Physiol*, 1999. **276**(3 Pt 2): p. H1113-6.
62. Dixon, A.K., et al., *Tissue distribution of adenosine receptor mRNAs in the rat*. *Br J Pharmacol*, 1996. **118**(6): p. 1461-8.
63. Peterfreund, R.A., et al., *Characterization and expression of the human A2a adenosine receptor gene*. *J Neurochem*, 1996. **66**(1): p. 362-8.
64. Mubagwa, K., K. Mullane, and W. Flameng, *Role of adenosine in the heart and circulation*. *Cardiovasc Res*, 1996. **32**(5): p. 797-813.
65. Jackson, E.K., C. Zhu, and S.P. Tofovic, *Expression of adenosine receptors in the preglomerular microcirculation*. *Am J Physiol Renal Physiol*, 2002. **283**(1): p. F41-51.

66. Weaver, D.R. and S.M. Reppert, *Adenosine receptor gene expression in rat kidney*. Am J Physiol, 1992. **263**(6 Pt 2): p. F991-5.
67. Yamaguchi, S., et al., *Adenosine A1 receptor mRNA in microdissected rat nephron segments*. Hypertension, 1995. **26**(6 Pt 2): p. 1181-5.
68. Kreisberg, M.S., E.P. Sillardorff, and T.L. Pallone, *Localization of adenosine-receptor subtype mRNA in rat outer medullary descending vasa recta by RT-PCR*. Am J Physiol, 1997. **272**(3 Pt 2): p. H1231-8.
69. Hansen, P.B.S., Jurgen, *Vasoconstrictor and vasodilator effects of adenosine in the kidney*. Am J Physiol Renal Physiol, 2003. **285**: p. 590-599.
70. Lader, A.S., et al., *cAMP activates an ATP-permeable pathway in neonatal rat cardiac myocytes*. Am J Physiol Cell Physiol, 2000. **279**(1): p. C173-87.
71. Lasley, R.D., et al., *Adenosine A1 receptor mediated protection of the globally ischemic isolated rat heart*. J Mol Cell Cardiol, 1990. **22**(1): p. 39-47.
72. Wyatt, D.A., et al., *Adenosine stimulates glycolytic flux in isolated perfused rat hearts by A1-adenosine receptors*. Am J Physiol, 1989. **257**(6 Pt 2): p. H1952-7.
73. Jackson, E.K., et al., *Possible role of adenosine deaminase in vaso-occlusive diseases*. J Hypertens, 1996. **14**(1): p. 19-29.
74. Pelleg, A., G. Katchanov, and J. Xu, *Autonomic neural control of cardiac function: modulation by adenosine and adenosine 5'-triphosphate*. Am J Cardiol, 1997. **79**(12A): p. 11-4.
75. Bullough, D.A., et al., *Adenosine activates A2 receptors to inhibit neutrophil adhesion and injury to isolated cardiac myocytes*. J Immunol, 1995. **155**(5): p. 2579-86.
76. Funaya, H., et al., *Plasma adenosine levels increase in patients with chronic heart failure*. Circulation, 1997. **95**(6): p. 1363-5.
77. Urbaschek, *Der Nucleotidabbau im Herzmuskel bei Sauerstoffmangel und seine mögliche Bedeutung für die Coronardurchblutung*. Die Naturwissenschaften, 1963. **Heft 6**: p. 228-229.
78. Willems, L., K.J. Ashton, and J.P. Headrick, *Adenosine-mediated cardioprotection in the aging myocardium*. Cardiovasc Res, 2005. **66**(2): p. 245-55.
79. Zucchi, R., et al., *Effect of cardiac A(1) adenosine receptor overexpression on sarcoplasmic reticulum function*. Cardiovasc Res, 2002. **53**(2): p. 326-33.
80. Dzau, V.J., R.C. Braun-Dullaeus, and D.G. Sedding, *Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies*. Nat Med, 2002. **8**(11): p. 1249-56.
81. Dubey, R.K., et al., *Smooth muscle cell-derived adenosine inhibits cell growth*. Hypertension, 1996. **27**(3 Pt 2): p. 766-73.
82. Shen, J., et al., *Novel mitogenic effect of adenosine on coronary artery smooth muscle cells: role for the A1 adenosine receptor*. Circ Res, 2005. **96**(9): p. 982-90.
83. Shen, J., et al., *Cell-Signaling Evidence for Adenosine Stimulation of Coronary Smooth Muscle Proliferation via the A1 Adenosine Receptor*. Circ Res, 2005.
84. Thurau, K., *Renal Hemodynamics*. Am J Med, 1964. **36**: p. 698-719.
85. Osswald, H., H.J. Schmitz, and O. Heidenreich, *Adenosine response of the rat kidney after saline loading, sodium restriction and hemorrhagia*. Pflugers Arch, 1975. **357**(3-4): p. 323-33.
86. Osswald, H., *Renal effects of adenosine and their inhibition by theophylline in dogs*. Naunyn Schmiedebergs Arch Pharmacol, 1975. **288**(1): p. 79-86.
87. Aki, Y., et al., *Effects of KW-3902, a selective and potent adenosine A1 receptor antagonist, on renal hemodynamics and urine formation in anesthetized dogs*. Pharmacology, 1997. **55**(4): p. 193-201.

88. Cook, C.B. and P.C. Churchill, *Effects of renal denervation on the renal responses of anesthetized rats to cyclohexyladenosine*. Can J Physiol Pharmacol, 1984. **62**(8): p. 934-8.
89. Murray, R.D. and P.C. Churchill, *Concentration dependency of the renal vascular and renin secretory responses to adenosine receptor agonists*. J Pharmacol Exp Ther, 1985. **232**(1): p. 189-93.
90. Nishiyama, A., E.W. Inscho, and L.G. Navar, *Interactions of adenosine A1 and A2a receptors on renal microvascular reactivity*. Am J Physiol Renal Physiol, 2001. **280**(3): p. F406-14.
91. Spinale, F.G., et al., *Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes*. Circulation, 1997. **96**(7): p. 2397-406.
92. Hagi D., B.M., Süselbeck T., Wolpert C., *Medikamente zur Therapie kardialer Ödeme*. Journal für Kardiologie (Österreich), 2004. **11**(4): p. 158-164.
93. Skott, O. and J.P. Briggs, *Direct demonstration of macula densa-mediated renin secretion*. Science, 1987. **237**(4822): p. 1618-20.
94. Leyssac, P.P., N.H. Holstein-Rathlou, and O. Skott, *Renal blood flow, early distal sodium, and plasma renin concentrations during osmotic diuresis*. Am J Physiol Regul Integr Comp Physiol, 2000. **279**(4): p. R1268-76.
95. Brown, R., et al., *Abolished tubuloglomerular feedback and increased plasma renin in adenosine A1 receptor-deficient mice*. Am J Physiol Regul Integr Comp Physiol, 2001. **281**(5): p. R1362-7.
96. Persson, A.E., et al., *Macula densa cell function*. Kidney Int Suppl, 1991. **32**: p. S39-44.
97. Osswald, H., *Metabolic control of organ function-does it apply to the kidney?*, in *The juxtaglomerular apparatus*, B. AEG Persson, Editor. 1988: Amsterdam. p. 155-166.
98. Bleich, M., E. Schlatter, and R. Greger, *The luminal K⁺ channel of the thick ascending limb of Henle's loop*. Pflugers Arch, 1990. **415**(4): p. 449-60.
99. Waldherr, R. and N. Gretz, *Natural course of the development of histological lesions after 5/6 nephrectomy*. Contrib Nephrol, 1988. **60**: p. 64-72.
100. Shimamura, T. and A.B. Morrison, *A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats*. Am J Pathol, 1975. **79**(1): p. 95-106.
101. Grond, J., et al., *Analysis of renal structural and functional features in two rat strains with a different susceptibility to glomerular sclerosis*. Lab Invest, 1986. **54**(1): p. 77-83.
102. Boudet, J., et al., *Experimental chronic renal failure in the rat by electrocoagulation of the renal cortex*. Kidney Int, 1978. **14**(1): p. 82-6.
103. Ritz, E., et al., *Protein restriction in the conservative management of uremia*. Am J Clin Nutr, 1978. **31**(9): p. 1703-11.
104. Laouari, D., et al., *Importance of proteins in the deterioration of the remnant kidneys, independently of other nutrients*. Int J Pediatr Nephrol, 1982. **3**(4): p. 263-9.
105. Jonas, E., et al., *Study on the renal handling of sex dependent proteins in male rats studied by micropuncture techniques and by the isolated perfused rat kidney*. Pflugers Arch, 1989. **414**(6): p. 634-9.
106. Purkerson, M.L., P.E. Hoffsten, and S. Klahr, *Pathogenesis of the glomerulopathy associated with renal infarction in rats*. Kidney Int, 1976. **9**(5): p. 407-17.
107. Wyss, M., et al., *Mitochondrial creatine kinase: a key enzyme of aerobic energy metabolism*. Biochim Biophys Acta, 1992. **1102**(2): p. 119-66.
108. Britton, C.V., A. Hernandez, and R. Roberts, *Plasma creatine kinase isoenzyme determinations in infants and children. Characterization in normal patients and after cardiac catheterization and surgery*. Chest, 1980. **77**(6): p. 758-60.

109. Ammann, P., et al., *Long-term outcome of acute myocarditis is independent of cardiac enzyme release*. Int J Cardiol, 2003. **89**(2-3): p. 217-22.
110. Rautenburg, H.W. and G. Szasz, [*Activity of various serum enzymes in children with congenital heart defects*]. Z Kreislaufforsch, 1972. **61**(10): p. 946-52.
111. Szasz, G., E.W. Busch, and H.B. Farohs, [*Serum creatine kinase. II. Experiences in myocardial infarct and other cardiologic diseases using the activated reverse reaction*]. Dtsch Med Wochenschr, 1971. **96**(23): p. 980-6 passim.
112. Karjalainen, J. and J. Heikkila, "*Acute pericarditis*": myocardial enzyme release as evidence for myocarditis. Am Heart J, 1986. **111**(3): p. 546-52.
113. Dimov, D. and B. Popov, *Changes in blood-serum enzymes in rheumatic myocarditis*. Cor Vasa, 1976. **18**(4): p. 319-22.
114. Oda, T., K. Hamamoto, and H. Morinaga, *Clinical aspects of nonrheumatic myocarditis in children*. Jpn Circ J, 1979. **43**(5): p. 433-40.
115. Anversa, P., et al., *Myocardial infarction in rats. Infarct size, myocyte hypertrophy, and capillary growth*. Circ Res, 1986. **58**(1): p. 26-37.
116. Funakoshi, H., et al., *Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function*. Circulation, 2006. **114**(21): p. 2240-50.